Mary Weiser-Evans
Concepts (426)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocytes, Smooth Muscle | 21 | 2023 | 260 | 3.910 |
Why?
| | PTEN Phosphohydrolase | 14 | 2025 | 162 | 3.850 |
Why?
| | Muscle, Smooth, Vascular | 25 | 2023 | 448 | 3.570 |
Why?
| | Vascular Remodeling | 8 | 2022 | 197 | 2.540 |
Why?
| | Atherosclerosis | 4 | 2023 | 402 | 2.130 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 58 | 1.550 |
Why?
| | Adventitia | 2 | 2022 | 42 | 1.240 |
Why?
| | Kruppel-Like Transcription Factors | 2 | 2020 | 74 | 1.130 |
Why?
| | Myofibroblasts | 3 | 2025 | 136 | 1.070 |
Why?
| | Stem Cells | 6 | 2023 | 612 | 1.040 |
Why?
| | Fibrosis | 12 | 2023 | 545 | 1.030 |
Why?
| | Lung Neoplasms | 19 | 2023 | 2568 | 0.940 |
Why?
| | Vascular System Injuries | 3 | 2023 | 77 | 0.930 |
Why?
| | Mice | 43 | 2024 | 18172 | 0.850 |
Why?
| | Cell Proliferation | 18 | 2021 | 2514 | 0.840 |
Why?
| | Neointima | 4 | 2022 | 17 | 0.800 |
Why?
| | Tunica Intima | 5 | 2010 | 76 | 0.750 |
Why?
| | Hypercholesterolemia | 1 | 2023 | 102 | 0.750 |
Why?
| | Spinocerebellar Ataxias | 1 | 2022 | 6 | 0.750 |
Why?
| | Galectin 3 | 1 | 2022 | 21 | 0.740 |
Why?
| | Animals | 63 | 2024 | 37697 | 0.720 |
Why?
| | Cell Differentiation | 10 | 2023 | 2008 | 0.690 |
Why?
| | Heart-Assist Devices | 4 | 2022 | 568 | 0.680 |
Why?
| | DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 16 | 0.650 |
Why?
| | Serum Response Factor | 3 | 2016 | 32 | 0.630 |
Why?
| | Carotid Artery Injuries | 5 | 2010 | 40 | 0.620 |
Why?
| | Chemokine CXCL12 | 2 | 2011 | 85 | 0.610 |
Why?
| | Coronary Restenosis | 1 | 2019 | 21 | 0.610 |
Why?
| | Mice, Knockout | 16 | 2024 | 3081 | 0.600 |
Why?
| | Cyclin D1 | 1 | 2019 | 68 | 0.600 |
Why?
| | Coronary Vessels | 2 | 2018 | 250 | 0.600 |
Why?
| | High-Throughput Screening Assays | 1 | 2020 | 158 | 0.580 |
Why?
| | Mice, Inbred C57BL | 22 | 2024 | 5967 | 0.570 |
Why?
| | Arteries | 4 | 2022 | 260 | 0.540 |
Why?
| | Cells, Cultured | 19 | 2025 | 4167 | 0.530 |
Why?
| | Vascular Diseases | 1 | 2019 | 246 | 0.510 |
Why?
| | Rats | 20 | 2019 | 5585 | 0.500 |
Why?
| | Heparan Sulfate Proteoglycans | 4 | 2003 | 24 | 0.490 |
Why?
| | Tumor Microenvironment | 8 | 2021 | 717 | 0.490 |
Why?
| | Mice, Transgenic | 9 | 2020 | 2180 | 0.480 |
Why?
| | PPAR gamma | 7 | 2019 | 176 | 0.470 |
Why?
| | Gene Expression Regulation | 6 | 2024 | 2608 | 0.460 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 1128 | 0.440 |
Why?
| | Cell Division | 8 | 2004 | 794 | 0.420 |
Why?
| | Hypertension, Pulmonary | 5 | 2023 | 1947 | 0.410 |
Why?
| | Disease Models, Animal | 17 | 2024 | 4483 | 0.410 |
Why?
| | Hypertension | 1 | 2022 | 1257 | 0.410 |
Why?
| | Acute Kidney Injury | 5 | 2023 | 829 | 0.400 |
Why?
| | Signal Transduction | 18 | 2019 | 5163 | 0.400 |
Why?
| | Hyperplasia | 5 | 2020 | 174 | 0.400 |
Why?
| | MicroRNAs | 2 | 2017 | 696 | 0.390 |
Why?
| | Protein Kinases | 4 | 2014 | 309 | 0.370 |
Why?
| | Transforming Growth Factor beta1 | 3 | 2023 | 169 | 0.350 |
Why?
| | Bone Marrow Cells | 2 | 2011 | 317 | 0.340 |
Why?
| | Ureteral Obstruction | 3 | 2021 | 65 | 0.330 |
Why?
| | Cell Movement | 5 | 2012 | 969 | 0.330 |
Why?
| | Muscle, Smooth | 2 | 2023 | 151 | 0.320 |
Why?
| | Kidney | 6 | 2021 | 1500 | 0.320 |
Why?
| | Macrophages | 4 | 2021 | 1496 | 0.310 |
Why?
| | Autocrine Communication | 2 | 2014 | 40 | 0.300 |
Why?
| | Cell Dedifferentiation | 3 | 2016 | 31 | 0.300 |
Why?
| | Phospholipases A2, Cytosolic | 1 | 2009 | 6 | 0.300 |
Why?
| | Angiotensin II | 3 | 2021 | 96 | 0.300 |
Why?
| | Group IV Phospholipases A2 | 3 | 2017 | 46 | 0.290 |
Why?
| | Platelet-Derived Growth Factor | 4 | 2020 | 88 | 0.290 |
Why?
| | Cisplatin | 3 | 2020 | 328 | 0.280 |
Why?
| | Carcinoma, Lewis Lung | 2 | 2019 | 16 | 0.270 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2004 | 32 | 0.260 |
Why?
| | Proteins | 2 | 2006 | 1013 | 0.260 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 4 | 2019 | 37 | 0.260 |
Why?
| | Proto-Oncogene Proteins c-akt | 7 | 2014 | 440 | 0.260 |
Why?
| | Heart Failure | 4 | 2023 | 2120 | 0.260 |
Why?
| | Male | 26 | 2024 | 70910 | 0.260 |
Why?
| | Rats, Sprague-Dawley | 9 | 2016 | 2523 | 0.250 |
Why?
| | Actins | 3 | 2018 | 427 | 0.250 |
Why?
| | Nuclear Proteins | 2 | 2023 | 727 | 0.250 |
Why?
| | Hypoxia | 2 | 2013 | 1166 | 0.250 |
Why?
| | Proto-Oncogene Proteins | 3 | 2004 | 622 | 0.250 |
Why?
| | TOR Serine-Threonine Kinases | 5 | 2014 | 436 | 0.240 |
Why?
| | Acetyltransferases | 1 | 2006 | 21 | 0.240 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2003 | 428 | 0.230 |
Why?
| | Adenocarcinoma | 5 | 2017 | 904 | 0.230 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 2 | 2019 | 268 | 0.230 |
Why?
| | Endothelial Cells | 2 | 2022 | 832 | 0.230 |
Why?
| | RNA Interference | 5 | 2014 | 469 | 0.230 |
Why?
| | Embryonic Development | 1 | 2006 | 123 | 0.230 |
Why?
| | Inflammation | 4 | 2023 | 2867 | 0.220 |
Why?
| | Fibromuscular Dysplasia | 1 | 2024 | 9 | 0.220 |
Why?
| | Myeloid Cells | 2 | 2019 | 148 | 0.220 |
Why?
| | Phosphatidylinositol 3-Kinases | 4 | 2010 | 371 | 0.220 |
Why?
| | Gene Expression | 3 | 2014 | 1496 | 0.220 |
Why?
| | Aortic Valve | 2 | 2025 | 360 | 0.220 |
Why?
| | Ribosomal Protein S6 | 1 | 2004 | 16 | 0.210 |
Why?
| | Phenotype | 10 | 2024 | 3184 | 0.210 |
Why?
| | Humans | 34 | 2025 | 142526 | 0.210 |
Why?
| | Inflammation Mediators | 2 | 2021 | 510 | 0.210 |
Why?
| | Corn Oil | 1 | 2023 | 5 | 0.210 |
Why?
| | Receptors, LDL | 1 | 2023 | 51 | 0.200 |
Why?
| | Azotemia | 1 | 2023 | 11 | 0.200 |
Why?
| | Proprotein Convertase 9 | 1 | 2023 | 87 | 0.200 |
Why?
| | Phosphorylation | 6 | 2019 | 1758 | 0.200 |
Why?
| | Lipoxygenase Inhibitors | 2 | 2021 | 35 | 0.190 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 168 | 0.190 |
Why?
| | Rejuvenation | 1 | 2022 | 19 | 0.190 |
Why?
| | Disease Progression | 7 | 2019 | 2831 | 0.190 |
Why?
| | Gene Regulatory Networks | 1 | 2024 | 315 | 0.180 |
Why?
| | Polycystic Kidney Diseases | 2 | 2019 | 73 | 0.180 |
Why?
| | Aortic Valve Stenosis | 1 | 2025 | 246 | 0.180 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 259 | 0.180 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2021 | 18 | 0.180 |
Why?
| | Aortic Valve Insufficiency | 1 | 2022 | 44 | 0.180 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2021 | 21 | 0.180 |
Why?
| | Fibroblasts | 2 | 2024 | 1033 | 0.180 |
Why?
| | Nephritis | 1 | 2021 | 22 | 0.180 |
Why?
| | Extracellular Matrix | 4 | 2021 | 556 | 0.180 |
Why?
| | DNA Helicases | 1 | 2023 | 144 | 0.180 |
Why?
| | Cytokines | 4 | 2021 | 2093 | 0.180 |
Why?
| | Assisted Circulation | 1 | 2021 | 25 | 0.180 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2021 | 10 | 0.180 |
Why?
| | Cholesterol | 1 | 2023 | 404 | 0.180 |
Why?
| | Adaptive Immunity | 2 | 2023 | 170 | 0.170 |
Why?
| | Zebrafish | 1 | 2006 | 509 | 0.170 |
Why?
| | Metformin | 2 | 2023 | 331 | 0.170 |
Why?
| | Transcription Factors | 4 | 2023 | 1728 | 0.170 |
Why?
| | Promoter Regions, Genetic | 5 | 2020 | 1254 | 0.170 |
Why?
| | Cell Line, Tumor | 9 | 2019 | 3546 | 0.170 |
Why?
| | Protein Kinase Inhibitors | 3 | 2023 | 927 | 0.170 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2021 | 147 | 0.170 |
Why?
| | Blotting, Western | 3 | 2019 | 1220 | 0.160 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2023 | 245 | 0.160 |
Why?
| | Aortic Diseases | 1 | 2021 | 120 | 0.160 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2017 | 1124 | 0.160 |
Why?
| | Jugular Veins | 1 | 2020 | 42 | 0.160 |
Why?
| | Female | 17 | 2024 | 76624 | 0.160 |
Why?
| | Intestines | 1 | 2023 | 355 | 0.160 |
Why?
| | Homeostasis | 2 | 2022 | 637 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 193 | 0.160 |
Why?
| | Arachidonate 5-Lipoxygenase | 2 | 2019 | 36 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 130 | 0.150 |
Why?
| | Wound Healing | 1 | 2022 | 354 | 0.150 |
Why?
| | GATA4 Transcription Factor | 1 | 2019 | 19 | 0.150 |
Why?
| | Myocytes, Cardiac | 2 | 2014 | 539 | 0.150 |
Why?
| | Kidney Tubules | 2 | 2019 | 117 | 0.150 |
Why?
| | Crohn Disease | 1 | 2023 | 256 | 0.150 |
Why?
| | Neovascularization, Physiologic | 1 | 2000 | 183 | 0.150 |
Why?
| | Azacitidine | 1 | 2020 | 149 | 0.150 |
Why?
| | Chromatin | 1 | 2023 | 546 | 0.150 |
Why?
| | Pulmonary Artery | 3 | 2021 | 1117 | 0.150 |
Why?
| | Catheterization | 4 | 2004 | 185 | 0.150 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 207 | 0.140 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2023 | 195 | 0.140 |
Why?
| | Bone Marrow | 2 | 2017 | 299 | 0.140 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2020 | 367 | 0.140 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.140 |
Why?
| | Metabolome | 1 | 2021 | 373 | 0.140 |
Why?
| | Flow Cytometry | 2 | 2019 | 1185 | 0.140 |
Why?
| | Epigenesis, Genetic | 1 | 2023 | 677 | 0.140 |
Why?
| | Sirolimus | 2 | 2014 | 277 | 0.140 |
Why?
| | Heart Ventricles | 2 | 2021 | 751 | 0.140 |
Why?
| | Interleukin-33 | 1 | 2017 | 50 | 0.130 |
Why?
| | Skin | 1 | 2022 | 769 | 0.130 |
Why?
| | Trans-Activators | 1 | 2020 | 401 | 0.130 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2019 | 214 | 0.130 |
Why?
| | Receptors, Complement | 1 | 2017 | 119 | 0.130 |
Why?
| | Epithelial Cells | 3 | 2019 | 1116 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 440 | 0.130 |
Why?
| | Gene Deletion | 2 | 2014 | 385 | 0.120 |
Why?
| | Ventricular Remodeling | 2 | 2023 | 266 | 0.120 |
Why?
| | Immunotherapy | 2 | 2018 | 649 | 0.120 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2021 | 919 | 0.120 |
Why?
| | Interferon-gamma | 1 | 2019 | 790 | 0.120 |
Why?
| | Energy Metabolism | 1 | 2021 | 935 | 0.120 |
Why?
| | Dinoprostone | 3 | 2016 | 181 | 0.120 |
Why?
| | Cell Cycle Proteins | 1 | 2019 | 634 | 0.120 |
Why?
| | B7-H1 Antigen | 1 | 2017 | 227 | 0.110 |
Why?
| | Focal Adhesion Kinase 1 | 3 | 2003 | 30 | 0.110 |
Why?
| | Autophagy | 2 | 2014 | 284 | 0.110 |
Why?
| | NF-kappa B | 2 | 2010 | 684 | 0.110 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2019 | 469 | 0.110 |
Why?
| | Retinoid X Receptors | 1 | 2014 | 38 | 0.110 |
Why?
| | Aorta | 3 | 2004 | 427 | 0.110 |
Why?
| | Complement Activation | 1 | 2017 | 409 | 0.110 |
Why?
| | Interleukin-6 | 3 | 2023 | 780 | 0.110 |
Why?
| | Pleural Neoplasms | 1 | 2014 | 27 | 0.110 |
Why?
| | Culture Media, Serum-Free | 2 | 2004 | 45 | 0.110 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2014 | 54 | 0.100 |
Why?
| | Gene Amplification | 1 | 2014 | 106 | 0.100 |
Why?
| | Mesothelioma | 1 | 2014 | 46 | 0.100 |
Why?
| | Leukotrienes | 1 | 2013 | 28 | 0.100 |
Why?
| | Kidney Diseases | 1 | 2017 | 412 | 0.100 |
Why?
| | Paracrine Communication | 1 | 2014 | 67 | 0.100 |
Why?
| | Oligonucleotides, Antisense | 2 | 2004 | 111 | 0.100 |
Why?
| | Eicosanoids | 1 | 2013 | 59 | 0.100 |
Why?
| | RNA | 1 | 2019 | 929 | 0.100 |
Why?
| | Myocardial Contraction | 1 | 2014 | 299 | 0.100 |
Why?
| | Monocytes | 1 | 2016 | 545 | 0.100 |
Why?
| | Iloprost | 2 | 2010 | 44 | 0.100 |
Why?
| | Macrophages, Alveolar | 1 | 2016 | 372 | 0.100 |
Why?
| | Macrophage Activation | 1 | 2014 | 192 | 0.100 |
Why?
| | MAP Kinase Signaling System | 3 | 2021 | 322 | 0.090 |
Why?
| | Up-Regulation | 2 | 2008 | 857 | 0.090 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2014 | 143 | 0.090 |
Why?
| | Tumor Burden | 3 | 2020 | 317 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 633 | 0.090 |
Why?
| | Immunohistochemistry | 4 | 2021 | 1727 | 0.090 |
Why?
| | Lipocalin-2 | 2 | 2023 | 79 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 951 | 0.090 |
Why?
| | Splenectomy | 1 | 2011 | 61 | 0.090 |
Why?
| | Transforming Growth Factor beta | 1 | 2014 | 479 | 0.090 |
Why?
| | Protein Processing, Post-Translational | 2 | 2004 | 468 | 0.090 |
Why?
| | Cyclooxygenase 2 | 2 | 2010 | 173 | 0.080 |
Why?
| | T-Lymphocytes | 2 | 2017 | 2016 | 0.080 |
Why?
| | Histone Deacetylases | 1 | 2012 | 210 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2012 | 217 | 0.080 |
Why?
| | Green Fluorescent Proteins | 1 | 2011 | 403 | 0.080 |
Why?
| | Frizzled Receptors | 1 | 2010 | 25 | 0.080 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2015 | 272 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2024 | 3604 | 0.080 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 629 | 0.070 |
Why?
| | Receptors, Epoprostenol | 1 | 2008 | 5 | 0.070 |
Why?
| | TRPP Cation Channels | 2 | 2019 | 81 | 0.070 |
Why?
| | Reperfusion Injury | 1 | 2011 | 292 | 0.070 |
Why?
| | Lung Injury | 1 | 2011 | 224 | 0.070 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2010 | 219 | 0.070 |
Why?
| | Glycoproteins | 1 | 2010 | 356 | 0.070 |
Why?
| | Antineoplastic Agents | 2 | 2017 | 2167 | 0.070 |
Why?
| | Epoprostenol | 1 | 2008 | 131 | 0.070 |
Why?
| | Adenosine Triphosphate | 2 | 2014 | 485 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2927 | 0.070 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2010 | 337 | 0.070 |
Why?
| | Receptors, CXCR4 | 1 | 2008 | 91 | 0.070 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 409 | 0.070 |
Why?
| | Culture Media, Conditioned | 2 | 2014 | 111 | 0.060 |
Why?
| | Gene Silencing | 2 | 2019 | 199 | 0.060 |
Why?
| | Biomarkers | 4 | 2023 | 4207 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 676 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 293 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 511 | 0.060 |
Why?
| | RNA, Messenger | 5 | 2010 | 2828 | 0.060 |
Why?
| | Apoptosis | 3 | 2020 | 2500 | 0.060 |
Why?
| | Middle Aged | 4 | 2024 | 35049 | 0.060 |
Why?
| | Mitogens | 1 | 2005 | 56 | 0.060 |
Why?
| | Neoplasm Transplantation | 2 | 2016 | 251 | 0.060 |
Why?
| | Acetylation | 1 | 2006 | 248 | 0.060 |
Why?
| | Protein Subunits | 1 | 2006 | 229 | 0.060 |
Why?
| | Animals, Genetically Modified | 1 | 2006 | 245 | 0.060 |
Why?
| | Mutation | 3 | 2023 | 4024 | 0.060 |
Why?
| | Gene Knockout Techniques | 2 | 2015 | 117 | 0.050 |
Why?
| | Pyrimidines | 2 | 2023 | 519 | 0.050 |
Why?
| | Pregnancy | 2 | 2016 | 7113 | 0.050 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 837 | 0.050 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2015 | 175 | 0.050 |
Why?
| | Cell Size | 2 | 2005 | 90 | 0.050 |
Why?
| | Chromones | 1 | 2004 | 44 | 0.050 |
Why?
| | Basement Membrane | 1 | 2003 | 32 | 0.050 |
Why?
| | Androstadienes | 1 | 2004 | 74 | 0.050 |
Why?
| | Gene Expression Profiling | 3 | 2016 | 1773 | 0.050 |
Why?
| | Acute-Phase Reaction | 1 | 2023 | 39 | 0.050 |
Why?
| | Embryo, Mammalian | 2 | 2003 | 235 | 0.050 |
Why?
| | Glycosaminoglycans | 1 | 2003 | 82 | 0.050 |
Why?
| | Furosemide | 1 | 2023 | 37 | 0.050 |
Why?
| | Tenascin | 1 | 2003 | 15 | 0.050 |
Why?
| | Peroxidases | 1 | 2003 | 29 | 0.050 |
Why?
| | Morpholines | 1 | 2004 | 129 | 0.050 |
Why?
| | Peroxidase | 2 | 2015 | 174 | 0.050 |
Why?
| | Fibronectins | 1 | 2003 | 135 | 0.050 |
Why?
| | Transfection | 3 | 2014 | 936 | 0.050 |
Why?
| | Murinae | 1 | 2022 | 6 | 0.050 |
Why?
| | Acrylamides | 1 | 2023 | 68 | 0.050 |
Why?
| | Metalloproteases | 1 | 2022 | 42 | 0.050 |
Why?
| | Ileum | 1 | 2023 | 110 | 0.050 |
Why?
| | Coculture Techniques | 2 | 2014 | 248 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2023 | 120 | 0.050 |
Why?
| | Matrix Metalloproteinases, Secreted | 1 | 2021 | 12 | 0.050 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 12 | 0.050 |
Why?
| | ADAMTS4 Protein | 1 | 2021 | 16 | 0.050 |
Why?
| | Cadherins | 2 | 2016 | 201 | 0.050 |
Why?
| | DNA Replication | 1 | 2003 | 245 | 0.040 |
Why?
| | Cell Line | 2 | 2018 | 2878 | 0.040 |
Why?
| | Adult | 3 | 2024 | 39715 | 0.040 |
Why?
| | Aged | 2 | 2018 | 25117 | 0.040 |
Why?
| | Aorta, Thoracic | 1 | 2003 | 285 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 91 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2003 | 672 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2023 | 288 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2021 | 137 | 0.040 |
Why?
| | Major Histocompatibility Complex | 1 | 2021 | 232 | 0.040 |
Why?
| | Blood Urea Nitrogen | 1 | 2020 | 54 | 0.040 |
Why?
| | Neoplasms | 1 | 2015 | 2761 | 0.040 |
Why?
| | Butadienes | 1 | 2020 | 37 | 0.040 |
Why?
| | Contractile Proteins | 1 | 2000 | 13 | 0.040 |
Why?
| | Leukocytes | 1 | 2021 | 296 | 0.040 |
Why?
| | Thiazolidinediones | 2 | 2011 | 136 | 0.040 |
Why?
| | Cell Fusion | 1 | 2000 | 49 | 0.040 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2000 | 53 | 0.040 |
Why?
| | Liver | 2 | 2023 | 1848 | 0.040 |
Why?
| | NADH, NADPH Oxidoreductases | 1 | 2019 | 25 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2014 | 785 | 0.040 |
Why?
| | Growth Substances | 1 | 2000 | 140 | 0.040 |
Why?
| | Genes, Tumor Suppressor | 1 | 2000 | 85 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 2000 | 532 | 0.040 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2023 | 615 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2019 | 28 | 0.040 |
Why?
| | Mesoderm | 1 | 2020 | 146 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 771 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2020 | 124 | 0.040 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2003 | 403 | 0.040 |
Why?
| | Tropoelastin | 1 | 1999 | 11 | 0.040 |
Why?
| | Receptors, Leukotriene | 1 | 2019 | 14 | 0.040 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2019 | 55 | 0.040 |
Why?
| | Indoles | 1 | 2023 | 475 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 445 | 0.040 |
Why?
| | Nitriles | 1 | 2020 | 192 | 0.040 |
Why?
| | Luciferases | 2 | 2010 | 149 | 0.040 |
Why?
| | Proteoglycans | 1 | 1999 | 109 | 0.040 |
Why?
| | Pyridones | 1 | 2020 | 194 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2003 | 887 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 251 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 985 | 0.030 |
Why?
| | Antibodies, Blocking | 1 | 2017 | 38 | 0.030 |
Why?
| | Complement C3d | 1 | 2017 | 67 | 0.030 |
Why?
| | Tumor Cells, Cultured | 2 | 2010 | 960 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2023 | 851 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 437 | 0.030 |
Why?
| | Complement C3 | 1 | 2017 | 190 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2016 | 107 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 287 | 0.030 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 279 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 421 | 0.030 |
Why?
| | Immunocompetence | 1 | 2016 | 47 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2024 | 2388 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 213 | 0.030 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 155 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2015 | 136 | 0.030 |
Why?
| | Organ Culture Techniques | 2 | 2007 | 157 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 199 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2015 | 160 | 0.030 |
Why?
| | Chemokines | 1 | 2016 | 223 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 345 | 0.030 |
Why?
| | Time Factors | 2 | 2017 | 7006 | 0.030 |
Why?
| | Caspase 3 | 1 | 2015 | 249 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 517 | 0.030 |
Why?
| | Tetrahydronaphthalenes | 1 | 2014 | 30 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 2 | 2005 | 39 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 922 | 0.030 |
Why?
| | Intracellular Space | 1 | 2014 | 67 | 0.030 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2014 | 21 | 0.030 |
Why?
| | Heart | 1 | 2018 | 627 | 0.030 |
Why?
| | Chemokine CCL2 | 1 | 2014 | 115 | 0.030 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2014 | 88 | 0.030 |
Why?
| | Pyridazines | 1 | 2014 | 56 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 512 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2016 | 230 | 0.030 |
Why?
| | Ventricular Myosins | 1 | 2014 | 32 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 208 | 0.030 |
Why?
| | Clone Cells | 1 | 2014 | 270 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2014 | 133 | 0.030 |
Why?
| | Cardiomegaly | 1 | 2014 | 172 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 215 | 0.020 |
Why?
| | Integrases | 1 | 2014 | 123 | 0.020 |
Why?
| | Imidazoles | 1 | 2014 | 251 | 0.020 |
Why?
| | Femoral Artery | 1 | 2014 | 188 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2013 | 185 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 701 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2016 | 522 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1772 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1262 | 0.020 |
Why?
| | Capillary Leak Syndrome | 1 | 2011 | 12 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 2017 | 588 | 0.020 |
Why?
| | Chemokine CXCL1 | 1 | 2011 | 77 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2012 | 215 | 0.020 |
Why?
| | Hypoglycemic Agents | 2 | 2011 | 1391 | 0.020 |
Why?
| | Benzamides | 1 | 2012 | 222 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 381 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2011 | 191 | 0.020 |
Why?
| | Cell Lineage | 1 | 2012 | 362 | 0.020 |
Why?
| | Snail Family Transcription Factors | 1 | 2010 | 18 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1471 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2010 | 82 | 0.020 |
Why?
| | Models, Animal | 1 | 2011 | 392 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2012 | 502 | 0.020 |
Why?
| | Matrix Metalloproteinases | 1 | 2010 | 95 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2011 | 310 | 0.020 |
Why?
| | Spleen | 1 | 2011 | 515 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 389 | 0.020 |
Why?
| | Myocardium | 1 | 2014 | 924 | 0.020 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2008 | 66 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2010 | 453 | 0.020 |
Why?
| | Sulindac | 1 | 2007 | 16 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2007 | 47 | 0.020 |
Why?
| | Metabolomics | 1 | 2013 | 712 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2008 | 194 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2008 | 159 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 567 | 0.020 |
Why?
| | Culture Media | 1 | 2007 | 163 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2007 | 305 | 0.020 |
Why?
| | Prognosis | 1 | 2016 | 4112 | 0.020 |
Why?
| | Transgenes | 1 | 2007 | 186 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2007 | 174 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1225 | 0.020 |
Why?
| | Genes, jun | 1 | 2005 | 10 | 0.010 |
Why?
| | Respiratory Mucosa | 1 | 2008 | 324 | 0.010 |
Why?
| | CCAAT-Enhancer-Binding Protein-delta | 1 | 2005 | 6 | 0.010 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2005 | 37 | 0.010 |
Why?
| | Heterotrimeric GTP-Binding Proteins | 1 | 2005 | 12 | 0.010 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2005 | 20 | 0.010 |
Why?
| | Blood Pressure | 1 | 2012 | 1745 | 0.010 |
Why?
| | Genetic Markers | 1 | 2005 | 343 | 0.010 |
Why?
| | Genotype | 1 | 2008 | 1866 | 0.010 |
Why?
| | Heparin Lyase | 1 | 2003 | 5 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2005 | 378 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 2053 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 759 | 0.010 |
Why?
| | Cattle | 1 | 2004 | 988 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2003 | 861 | 0.010 |
Why?
| | Binding Sites | 1 | 2003 | 1317 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2003 | 522 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 1999 | 81 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1999 | 319 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1999 | 328 | 0.010 |
Why?
| | Muscle Development | 1 | 1999 | 115 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1500 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 1821 | 0.010 |
Why?
| | Gestational Age | 1 | 1999 | 961 | 0.010 |
Why?
| | DNA | 1 | 1999 | 1447 | 0.010 |
Why?
|
|
Weiser-Evans's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|